Ensuring the Biological Integrity of Raw Materials

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s31-s34

A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.

Contamination with microbes, mycoplasma, viruses, and adventitious agents can be a significant problem in biopharmaceutical manufacturing. Although contamination can occur from many sources, raw materials are the most significant source of contamination. 

Strategies for preventing contamination including upfront testing of materials, barrier disinfection methods, and adhering to best practices in processing and sanitation are explored.

Avoidance of animal-based raw materials, as well as careful sourcing of any materials used, are discussed.

Download

Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook

.

 

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.